Darwazah,Said Acquires 70,251 Shares of Hikma Pharmaceuticals Plc (HIK) Stock
Hikma Pharmaceuticals Plc (LON:HIK) insider Darwazah,Said acquired 70,251 shares of the stock in a transaction dated Thursday, September 15th. The shares were bought at an average cost of GBX 2,122 ($28.26) per share, with a total value of £1,490,726.22 ($1,985,517.08).
Darwazah,Said also recently made the following trade(s):
- On Friday, August 26th, Darwazah,Said acquired 200,000 shares of Hikma Pharmaceuticals Plc stock. The shares were bought at an average cost of GBX 2,160 ($28.77) per share, with a total value of £4,320,000 ($5,753,862.55).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2118.4751 on Monday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00. The stock’s 50 day moving average price is GBX 2,273.76 and its 200 day moving average price is GBX 2,221.42. The stock’s market cap is GBX 4.79 billion.
A number of equities analysts recently issued reports on the company. Jefferies Group lowered their price target on Hikma Pharmaceuticals Plc from GBX 2,990 ($39.82) to GBX 2,500 ($33.30) and set a “buy” rating for the company in a report on Monday, September 12th. Barclays PLC reaffirmed an “overweight” rating and issued a GBX 2,800 ($37.29) price target on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 4th. Numis Securities Ltd reaffirmed a “hold” rating and issued a GBX 2,660 ($35.43) price target on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, August 24th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, June 24th. Finally, Morgan Stanley lowered their price target on Hikma Pharmaceuticals Plc from GBX 2,700 ($35.96) to GBX 2,500 ($33.30) and set an “equal weight” rating for the company in a report on Friday, August 12th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Hikma Pharmaceuticals Plc presently has a consensus rating of “Buy” and an average price target of GBX 2,520.90 ($33.58).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.